Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Outlook Therapeutics Inc (OTLK)  
$7.78 0.45 (6.14%) as of 4:30 Fri 5/17


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 123,000,000
Market Cap: 956.94(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.78 - $11.94
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 6.9
Insider 6 Months    : 6.9
Insider 3/6 Months : 13.9
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and launching ophthalmic formulation of bevacizumab approved by the U.S. Food and Drug Administration for use in retinal indications. ONS-5010 (LYTENAVA (bevacizumab-vikg)), Co.'s sole product candidate in active clinical development, is an investigational ophthalmic formulation of bevacizumab, which it is developing to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. Co.'s clinical program for ONS-5010 in wet AMD involves three clinical trials, which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 778,652 778,652 778,652 1,071,920
Total Buy Value $48,485 $48,485 $48,485 $414,759
Total People Bought 3 3 3 7
Total Buy Transactions 3 3 3 13
Total Shares Sold 0 0 0 951,155
Total Sell Value $0 $0 $0 $1,090,296
Total People Sold 0 0 0 2
Total Sell Transactions 0 0 0 5
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 151
  Page 4 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Hilzinger Kurt J Director   –       •      –    2019-01-09 4 B $0.73 $2,038 D/D 2,792 98,629 2.31     -
   Hilzinger Kurt J Director   –       •      –    2019-01-08 4 B $0.65 $4,167 D/D 6,410 95,837 2.31     -
   Hilzinger Kurt J Director   –       •      –    2019-01-07 4 B $0.63 $3,255 D/D 5,166 89,427 2.31     -
   Hilzinger Kurt J Director   –       •      –    2019-01-04 4 B $0.59 $3,661 D/D 6,205 84,261 2.31     -
   Hilzinger Kurt J Director   –       •      –    2019-01-03 4 B $0.59 $2,478 D/D 4,200 78,056 2.31     -
   Hilzinger Kurt J Director   –       •      –    2019-01-02 4 B $0.59 $968 D/D 1,640 73,856 2.31     -
   Sukhtian Faisal Ghiath Director   –       •       •   2019-01-02 4 A $0.93 $4,000,000 D/D 4,288,624 61,481,879     -
   Hilzinger Kurt J Director   –       •      –    2018-12-31 4 B $0.59 $6,696 D/D 11,349 72,216 2.39     -
   Hilzinger Kurt J Director   –       •      –    2018-12-28 4 B $0.52 $6,193 D/D 11,910 60,867 2.39     -
   Hilzinger Kurt J Director   –       •      –    2018-12-27 4 B $0.51 $372 D/D 730 48,957 2.31     -
   Hilzinger Kurt J Director   –       •      –    2018-12-26 4 B $0.54 $3,086 D/D 5,714 48,227 2.31     -
   Hilzinger Kurt J Director   –       •      –    2018-12-24 4 B $0.66 $735 D/D 1,113 42,513 2.31     -
   Hilzinger Kurt J Director   –       •      –    2018-12-21 4 B $0.65 $2,340 D/D 3,600 41,400 2.31     -
   Thurman Randy H Director   –       •      –    2018-12-21 4 B $0.68 $10,251 D/D 15,000 15,000 2.39     -
   Sukhtian Faisal Ghiath Director   –       •       •   2018-12-03 4 A $0.93 $4,000,000 D/D 4,288,624 57,193,255     -
   Sukhtian Faisal Ghiath Director   –       •       •   2018-11-07 4 A $0.93 $7,999,999 D/D 8,577,248 52,904,631     -
   Kenyon Lawrence A CEO, Pres, CFO, Treas & Secy   •       •      –    2018-09-18 4 S $0.87 $8,807 D/D (10,100) 57,213     -
   Bahrt Kenneth Chief Medical Officer   •       –      –    2018-06-25 4 S $0.85 $6,507 D/D (7,700) 47,120     -
   Sukhtian Ghiath M. Director   –       •       •   2018-06-20 4 A $0.00 $0 D/D 31,572,617 44,327,383     -
   Sukhtian Ghiath M. Director   –       •       •   2018-06-08 4 A $0.98 $6,217,948 D/D 6,377,383 12,754,766     -
   Sukhtian Ghiath M. Director   –       •       •   2018-05-14 4 A $0.98 $6,217,948 D/D 6,377,383 6,377,383     -
   Mohan Pankaj President & CEO   •       •       •   2018-01-04 4 S $1.16 $72,580 D/D (62,569) 7,056,553     -
   Mohan Pankaj President & CEO   •       •       •   2018-01-03 4 S $1.18 $61,487 D/D (52,108) 7,119,122     -
   Bahrt Kenneth Chief Medical Officer   •       –      –    2017-12-22 4 S $1.13 $29,566 D/D (26,165) 54,820     -
   Yamashita Elizabeth A. VP, Regulatory Affairs   •       –      –    2017-12-22 4 S $1.13 $18,272 D/D (16,170) 64,648     -
  151 Records found
  1  2  3  4  5  6  7   
  Page 4 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us